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Since its inception in 1955, the National Cancer Institute’s (NCI)
Developmental Therapeutics Program (DTP) has utilized various
experimental screening models to select agents for evaluation as
clinical candidates. The philosophical position from which this
endeavour proceeded was that elucidation of empirically defined
anti-tumor activity in a model would translate into some likelihood
of activity in human cancer. The choice of specific screening
models was based primarily on response of the models to agents
already identified as clinically active (Gellhorn and Hirschberg,
1955; Zubrod et al, 1966). Initially, 3 transplanted rodent models
were used: Sarcoma 180, Carcinoma 755 and Leukaemia L1210.
The spectrum of models was then broadened, retaining L1210,
which was discerned to be the most predictive of clinical activity,
and adding a series of transplanted rodent models. This scheme was
replaced in 1975 by the murine P388 leukaemia model, which was
utilized as a pre-screen and followed by a panel of tumours. This
panel first included only rodent tumours but was later enhanced to
include human tumour xenografts (Venditti, 1981; Venditti et al,
1984). The human tumour xenografts were employed with the
intent of their serving as potentially better predictors of clinical
activity against solid human tumours. 
In early 1990, the P388 pre-screen was replaced by an in vitro
human tumour cell line assay comprised of 60 different cell types
(Alley et al, 1988; Monks et al, 1991; Paull et al, 1995). Agents
selected on the basis of potency, selective activity against a partic-
ular disease category, and/or differential activity against a few
specific cell lines were then evaluated against a small number of
sensitive human tumours in the nude mouse xenograft model
(Dykes et al, 1992; Plowman et al, 1997) as a basis for selecting
compounds for further preclinical development. Owing to the
large numbers of molecules emerging from the in vitro screen as
candidates for xenograft testing, in 1995 this development path
was further modified to include a hollow fibre (HF) assay
(Hollingshead et al, 1999), activity in which was a prerequisite for
study in classical xenograft models. The HF model, where cells
are introduced from tissue culture into semi-permeable fibres
in mouse intraperitoneal (i.p.) or subcutaneous (s.c.) space and
exposed to test agents, is a rapid and efficient means of selecting
compounds with the potential for in vivo activity in conventional
xenografts in pilot and ‘training’ sets of compounds. 
This drug screening and development scheme remains an
empirical one, as compounds are prioritized for development
based on the definition of anti-proliferative in vitro and in vivo
responses. Owing to an emerging understanding of the molecular
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Summary An analysis of the activity of compounds tested in pre-clinical in vivo and in vitro assays by the National Cancer Institute’s
Developmental Therapeutics Program was performed. For 39 agents with both xenograft data and Phase II clinical trials results available, 
in vivo activity in a particular histology in a tumour model did not closely correlate with activity in the same human cancer histology, casting
doubt on the correspondence of the pre-clinical models to clinical results. However, for compounds with in vivo activity in at least one-third of
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assay which were also tested against in vivo tumour models, the likelihood of finding xenograft activity in at least one-third of the in vivo
models tested rose with increasing intraperitoneal hollow fibre activity, from 8% for all compounds tested to 20% in agents with evidence of
response in more than 6 intraperitoneal fibres (P < 0.0001). Intraperitoneal hollow fibre activity was also found to be a better predictor of
xenograft activity than either subcutaneous hollow fibre activity or intraperitoneal plus subcutaneous activity combined. Since hollow fibre
activity was a useful indicator of potential in vivo response, correlates with hollow fibre activity were examined for 2304 compounds tested in
both the NCI 60 cell line in vitro cancer drug screen and hollow fibre assay. A positive correlation was found for histologic selectivity between
in vitro and hollow fibre responses. The most striking correlation was between potency in the 60 cell line screen and hollow fibre activity; 56%
of compounds with mean 50% growth inhibition below 10–7.5 M were active in more than 6 intraperitoneal fibres whereas only 4% of
compounds with a potency of 10–4 M achieved the same level of hollow fibre activity (P < 0.0001). Structural parameters of the drugs analysed
included compound molecular weight and hydrogen-bonding factors, both of which were found to be predictive of hollow fibre activity. © 2001
Cancer Research Campaign http://www.bjcancer.com
Keywords: anticancer drug discovery; in vitro-to-in vivo correlations; clinical trials 
1424
Received 10 August 2000 
Revised 13 February 2001 
Accepted 19 February 2001 
Correspondence to: EA Sausville 
British Journal of Cancer (2001) 84(10), 1424–1431
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.1796, available online at http://www.idealibrary.com on  http://www.bjcancer.comCorrelations between preclinical and clinical activity 1425
British Journal of Cancer (2001) 84(10), 1424–1431 © 2001 Cancer Research Campaign
basis for human cancer, great interest exists in transitioning from
an empirical to a potentially more rational, molecular-targeted
approach to the discovery and development of novel cancer thera-
peutics (Sausville and Feigal, 1999). Of particular interest will be
the design of models to detect the action of compounds on partic-
ular predefined targets. The ‘performance features’ of compounds
that have been evaluated in the ‘empirical’ development scheme
may be of value in serving as a baseline against which newer
compounds and models may be compared. 
To this end, we present here an experience attempting to corre-
late activity in the clinic with antecedent activity in preclinical
models. In addition, we present NCI’s cumulative experience with
the performance of the HF assay in relation to in vitro activity and
to certain chemical characteristics of the compounds. 
MATERIALS AND METHODS 
Agents used 
Data for 39 agents which had completed phase II trials (Table 1)
and which had also been evaluated against in vivo tumour models
were compiled. 13 of these compounds were ‘standard’ agents and
the remaining 26 were compounds for which NCI INDs were filed
between 1980 and 1996. 
For an analysis of factors affecting xenograft outcome, 1228
compounds for which both current xenograft data and activity in
NCI’s 60 cell line in vitro anti-cancer drug screen were available.
The compounds were tested in a median of 5 xenograft experi-
ments (range 1–131) and a median of 4 different histologies (range
1–14). In addition, 564 of these had been evaluated in the HF
assay. Compounds were selected for xenograft testing at least
partially on the basis of performance in the 60 cell line assay
and/or the HF assay. Of these, 756 are open, publicly available
compounds and 472 are discreet, confidential structures. 
A set of 2304 compounds which was evaluated in the 60 cell
line assay (1252 open, 1052 discreet) and referred for evaluation
and testing in the HF assay was analysed. The compounds repre-
sented a wide variety of structural types, and ranged in in vitro
potency from GI50s (concentration of drug which achieved 50%
growth inhibition averaged over all 60 cell lines) of 100 mM to less
than 10 nM. Reasons for referring the compounds for HF evalua-
tion included selective activity against cell lines of a particular
histologic type, ‘non-standard’ mechanism of action as determined
by the COMPARE pattern recognition algorithm (Paull et al,
1989), as well as compounds which were structurally novel and
possibly representing novel chemotypes directed against defined
mechanisms (e.g. topoisomerase inhibition). Lists of the non-
proprietary compounds in these data sets are available at
http://dtp.nci.nih.gov/docs/bjcwebsup.html. 
Clinical response 
Clinical response rate of particular histologic tumour types to the
26 NCI IND agents was reviewed in patients from all completed
phase II trials with at least 9 patients; the trials were conducted
under NCI sponsorship or otherwise included in Cancer Therapy
Evaluation Program records, and were carried out with appropriate
ethical committee approval. A ‘positive’ phase II trial involved an
objective 50% reduction in tumour size in at least 20% of patients.
For the 13 standard agents, response rates were taken from DeVita
(De Vita et al, 1982, 1985, 1989, 1993, 1997). All abstractions
were done by professional abstractors from EMMES Corporation
(Potomac, MD). 
Preclinical models 
Compounds were tested in a variety of xenograft models
according to methods described by Dykes and Plowman (Dykes
et al, 1992; Plowman et al, 1997). Two levels of response were
considered. For ‘survival’ models, the 2 thresholds were increased
life span of 25% or 50%. In other subcutaneous xenograft models,
estimation of tumour weight allowed calculation of treated/control
weight ratios (T/C), with thresholds of 40% and 10% indicative of
a level or degree of activity in this analysis. Agents were in all
cases studied at or below the maximum tolerated dose, defined as
the greatest quantity of test agent given as an acute dose which a
mouse is able to survive for 11 days. 
Agents were tested in the HF assay as described by
Hollingshead (Hollingshead et al, 1999). A standard panel of 12
tumour cell lines are used for routine HF screening, including 
non-small cell lung carcinoma lines NCI-H23 and NCI-H522,
breast carcinoma lines MDA-MB-231 and MDA-MB-435, colon
sarcoma lines SW-620 and COLO 205, melanoma lines LOX and
Table 1 NSC numbers and common names for 39 phase II clinical agents 
NSC Number Common name 
740 Methotrexate 
3053 Actinomycin-D 
3088 Chlorambucil 
8806 Melphalan 
19893 5-FU 
26271 Cyclophosphamide 
26980 Mitomycin C 
45388 Dacarbazine 
49842 Vinblastine 
105014 2-CDA 
119875 Cisplatin 
123127 Adriamycin HCL 
125066 Bleomycin 
125973 Paclitaxel 
141633 Homoharringtonine 
172112 Spiromustine 
253272 Caracemide 
264880 Dihydro-5-azacytidine 
267469 Deoxydoxorubicin 
269148 Menogaril 
281272 Fazarabine 
286193 Tiazofurin 
308847 Amonafide 
312887 Fludarabine phosphate 
325319 Didemnin B 
332598 Rhizoxin 
336628 Merbarone 
337766 Bisantrene 
339004 Chloroquinoxaline sulfonamide 
347512 Flavone acetic acid 
349174 Piroxantrone hydrochloride 
352122 Trimetrexate 
356894 Deoxyspergualin 
361456 Pyrazine diazohydroxide 
366140 Pyrazoloacridine 
409962 BCNU 
609699 Hycamptamine 
616348 CPT-11 (irinotecan) 
628503 Taxotere (docetaxel) 1426 JI Johnson et al 
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UACC-62, ovarian carcinoma lines OVCAR-3 and OVCAR-5,
and glioma lines U251 and SF-295. The cells, at densities of 2–10
´ 106 cells ml,–1 are flushed into polyvinylidine fluoride fibres
having an internal diameter of 1 mm. The fibres are heat-sealed at
2 cm intervals, and the samples are placed into tissue culture
medium and incubated for 24 to 48 hours prior to implantation. On
the day of implantation, samples of each tumour cell line prepara-
tion are quantitated for viable cell mass by a stable endpoint MTT
assay so that the time zero cell mass is known. Each mouse
receives 3 i.p. implants representing 3 of the tumour cell lines, and
3 s.c. implants of the same 3 tumour cell lines. Mice are treated
with experimental agents, which have been solubilized using 10%
DMSO in saline and tween 80 (0.05%), on day 3 or 4 following
fibre implantation and continuing daily for 4 days. Each agent is
administered by i.p. injection at 2 dose levels. The dose levels are
determined from the single dose i.p. maximum tolerated dose
(MTD) for each test agent; the high dose being the MTD ´ 0.375
and the low dose being the MTD ´ 0.25. The fibres are collected
from the mice on the day following the fourth treatment and viable
cells estimated by the MTT assay. A 50% or greater reduction in
percent net growth in the treated samples compared to the vehicle
control samples is considered a positive result. A total of 48 fibres
is treated in a standard experiment (12 cell lines ´ 2 implant sites ´
2 dose levels). Each treated fibre exhibiting at least a 50% net
reduction in cell growth is assigned an arbitrary score of 2 points,
and the number of fibres reaching this level in the i.p. and s.c.
compartments are recorded separately. Any cell lines in which cell
kill is observed are also recorded. 
Criteria were initially established for compound activity using a
training set of 80 randomly selected compounds which were eval-
uated in both the HF and xenograft assays. The goal of the training
set was to define a scoring system which allowed bias in favour of
detecting all compounds with xenograft activity, defined as ≤40%
T/C in at least one tumour xenograft. Criteria for activity in the HF
assay which accomplished this goal were thus: 20 or more total
points (any combination of points in the i.p. and s.c. fibres), 8 or
more points in s.c. fibres, or an observation of cell kill in any fibre
in either the i.p. or s.c. compartment. 
The NCI in vitro anti-cancer drug screen has been described in
detail previously (Alley et al, 1988; Monks et al, 1991). It utilizes
60 different human tumour cell lines representing leukaemia, mela-
noma, lung, colon, brain, ovary, breast, prostate and kidney cancers.
For a typical screening experiment, cells are inoculated into 
96-well microtitre plates and allowed to incubate for 24 hours.
Experimental drugs are solubilized in dimethyl sulfoxide and stored
frozen prior to use. At the time of drug addition, an aliquot of frozen
concentrate is thawed and diluted with complete medium. 4,10-fold
or 1/2 log additional serial dilutions are made to provide a total of
5 drug concentrations plus control. Following drug addition, the
plates are incubated for an additional 48 hours. Sulforhodamine B
solution is added to each well, and bound stain is solubilized and
the absorbance read. The percentage growth is calculated at each of
the drug concentration levels. 3 dose response parameters are calcu-
lated for each experimental agent: growth inhibition of 50% (GI50),
total growth inhibition (TGI), and the concentration of drug
resulting in a 50% reduction in measured protein (LC50). 
Structural characteristics 
Chem-X, a product of Chemical Design, Ltd (Oxfordshire, UK),
was used to quantitate aspects of structural characteristics such as
the number of hydrogen bonds, hydrogen bond donors and accep-
tors. Molecular weights were taken as calculated from molecular
formulas from the DTP Drug Information System. 
Statistical tests 
c2 analyses were conducted to examine the effect of various
factors on in vivo outcomes; where insufficient data were available
for a c2 analysis, the Fisher’s exact test was employed. The
Spearman rank correlation coefficient was used to correlate in vivo
activity with clinical responses; this statistic is defined as the more
familiar Pearson correlation of the data, after the data values for
each measure of activity have been replaced by their respective
ranks. The Spearman rank correlation is more appropriate than the
Pearson correlation in situations where the data are not normally
distributed. A Student’s t-test was used in comparing mean
MW and means for hydrogen-bonding characteristics. Statistical
significance was set at the 99% confidence level (P < 0.01). 
RESULTS 
Indicators of clinical activity 
For 39 clinical agents, relationships between xenograft response
levels, averaged by histology, and the phase II response rates were
investigated. The Spearman rank correlation coefficients (r) for all
histologies are plotted in Figure 1. Only non-small cell lung
(NSCL) xenografts were predictive of clinical activity in the same
histology (r = 0.814, P = 0.004). Breast xenograft models were the
most useful for predicting clinical response against any disease,
correlating with clinical activity against NSCL (r = 0.565, 
P = 0.008), melanoma (r = 0.540, P = 0.007) and ovarian (r = 0.611,
P = 0.003) cancer, but interestingly, not with clinical breast cancer.
Activity in colon xenografts predicted for clinical melanoma
response (r = 0.532, P = 0.005). There were no other correlations
that met the criteria for statistical significance. The number of
xenograft models with a T/C ≤40% or ILS ³25% was compared
with the presence of clinical activity. Clinical activity was found in
only 2/6 agents (33%) with activity in fewer than one-third or
more of tested xenograft models, but was found in 21/33 agents
(64%) with activity in one-third or more of tested xenograft
models (Figure 2A); undoubtedly due to the small number of
agents, this difference is not statistically significant (P = 0.14). The
comparison was also repeated using a more stringent definition of
clinical activity, demanding that agents tested in multiple disease
demonstrate response in at least 2 diseases. Applying this more
strigent definition, clinical activity was found in 0/6 agents (0%)
which had activity in fewer than one-third of tested pre-clinical
xenograft models, whereas 15/33 agents (45%) with activity in
one-third or more of tested pre-clinical xenograft models had clin-
ical activity (P = 0.04) (Figure 2B). The analyses were repeated,
increasing the threshold for xenograft activity to a T/C ≤ 10% or
ILS ³50%, a comparison which yielded no useful correlations
between overall xenograft activity and either definition of clinical
activity. 
Indicators of xenograft activity 
To assess how HF activity might be related to predicting activity in
some xenograft model, we considered the likelihood of responses
in xenograft models as a function of HF activity. Table 2A showsCorrelations between preclinical and clinical activity 1427
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that using compounds with studies in at least 4 different tumour
types, there exists a strong correlation (P < 0.0001) between
activity in HF placed in the peritoneal compartment and ultimate
xenograft activity, so that compounds with activity in >6 perito-
neal fibres had a 20% likelihood of subsequent xenograft activity
while compounds with activity in ≤6 fibres had a 3% rate of xeno-
graft activity. One criticism of this correlation is that it would be
relevant only to intraperitoneal xenografts. Table 2B does in fact
show that activity in ³10 peritoneal fibres does, perhaps not
surprisingly, show activity in 45% of peritoneal xenografts.
However, Table 2C reinforces the correlation of activity in perito-
neal fibres to activity in any xenograft model, including subcuta-
neous models. Note that for this comparison, if the threshold for
HF activity is raised to more than 6 fibres, at least two-thirds of the
xenograft active compounds become false negatives. Interestingly,
activity in subcutaneously placed fibres did not correlate with
likely activity in either peritoneal or subcutaneous xenografts (data
not shown). Since HF response did not account for all of the xeno-
graft active agents, the nature of the compounds and test condi-
tions for these agents were examined. In all of these compounds,
the xenograft activity was obtained using a route, schedule or other
experimental condition not available or not routinely used in the
HF assay (data not shown); in the case of some slower growing
solid tumours, for example, activity was obtained using Q4Dx3 or
Q7Dx3 schedules which are not available in the standard 4-day HF
assay. 
A second general indicator of likely xenograft activity actually
emerges from consideration of in vitro screening data. Tables 3A
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Figure 1 In vivo activity and clinical activity by disease type The median number of agents per correlation was 12 (range 2–27). For the statistically significant
correlations, the median was 21 (range 10–26). The number of xenograft systems per histology ranged between 7 and 9 for all histologies except for sarcoma
which included only one xenograft model. * – statistically significant correlation
Table 2A IP HF activity vs xenograft activity (at least 4 tumours tested) 
% of xenograft 
models active 
Responsive IP fibres <33% ³33% Total % active in 33% of
xenografts 
0–6 fibres 179 6 185 3% 
³7 fibers 57 14 71 20% 
Total 236 20 256 8% 
c2 = 19.3, P < 0.0001 
Table 2B IP HF activity vs activity in IP xenograft models 
Responsive  Agents active in  Agents inactive in  Total % active 
IP fibres IP xenograft IP xenograft
0–3 fibres 32 231 263 12% 
4–6 fibres 23 85 108 21% 
7–9 fibres 16 30 46 35% 
³10 fibres 19 23 42 45% 
Total 90 369 459 20% 
c2 = 33.7, P < 0.0001 
Compounds were studied in a median of one ip xenograft model, with some
compounds being tested in as many as 8 models. 
Table 2C IP HF activity vs activity in any xenograft model 
Responsive  Agents active in  Agents inactive in  Total % active 
IP fibres any xenograft all xenograft
0–3 fibres 84 212 296 28% 
4–6 fibres 43 84 127 34% 
7–9 fibres 26 31 57 46% 
³10 fibres 36 21 57 63% 
Total 189 348 537 35% 
c2 = 28.4, P < 0.0001and 3B demonstrate that compounds with evidence of selective
activity for successively greater numbers of lung or breast carci-
noma cell lines had successively increased likelihood of demon-
strating activity in lung or breast xenograft models. Compounds
with evidence of in vitro selectivity in 6 or more lung cell lines
exhibited activity in 33% (compared to 17.5% overall) of corre-
sponding xenografts. Compounds with evidence of in vitro selec-
tivity in breast cell lines were even more likely (44%) to be active
in the corresponding xenografts (compared to 21% overall). When
this effort was extended to other histologies, no other significant
correlations emerged (data not shown). 
Indicators of HF activity 
Given that HF response can, to a certain extent, predict some level
of xenograft activity, it becomes of interest to enquire if predictors
of activity in the HF model can be gleaned from in vitro screening
data or structural properties of the molecules. Table 4 demon-
strates that in the case of breast, lung, ovarian, CNS and melanoma
cell lines, selective activity in the particular in vitro panel does
show a trend toward correlating with emergence of activity in the
corresponding cell types in the HF panel. For example, 48% of the
agents that were selective for breast cell line activity in vitro also
showed activity (growth inhibition of 50%) in the breast carci-
noma HF, compared to 39% of compounds selected for study in
hollow fibres for any reason. Colon carcinoma cell line activity did
not correlate with HF colon cancer cell line activity. 
Greater potency in the 60 cell line assay, as indicated by the
GI50, correlates exceptionally well with increasing activity in the
HF model with peritoneal fibres (Figure 3) (P < 0.0001). For
example, 37% of compounds with a log10 GI50 of at least -7.5
demonstrate activity in at least 10 out of 24 i.p. fibres, whereas the
fraction of all compounds with this level of activity in the HF
assay is only 6%. Similar analyses were carried out utilizing
activity in s.c. fibres and i.p. plus s.c. fibres. As with the compar-
ison of HF-to-xenografts, these analyses showed that activity in
the s.c. fibres did not correlate with in vitro 60 cell line potency,
and that activity in the i.p. plus s.c. fibres was less correlative than
the i.p. fibre response alone (data not shown). 
The mean GI50 for only the 12 cell lines used in the HF assay
was also examined to determine if this measure was more correla-
tive than the average potency in all 60 cell lines. Although 12 cell
line in vitro potency still correlates positively with HF activity, the
correlation is not as striking as that obtained using the 60 cell line
GI50 (data not shown). 
‘Differential’ activity of a compound between distinct cell types
in the in vitro screen may be an indication of a basis for expecting
selective anti-proliferative effect in vivo and ultimately in the
1428 JI Johnson et al 
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Table 3A Analysis of in vitro lung histology response vs lung xenograft response 
No. lung lines with GI50 Lung xenograft inactive Lung xenograft active Total tested % active c2 P
< mean GI50
3 299 79 378 21% 9.99 0.00158 
4 206 70 276 25% 24.1 <0.0001 
5 133 56 189 30% 29.6 <0.0001 
6 78 38 116 33% 23.8 <0.0001 
Table 3B Analysis of in vitro breast histology response vs breast xenograft response 
No. breast lines with GI50 Breast xenograft inactive Breast xenograft active Total tested % active c2 P
< mean GI50
3 189 53 242 22% 0.665 0.415 
4 159 46 205 22% 0.884 0.347 
5 103 38 141 27% 5.62 0.0180 
6 34 27 61 44% 25.0 <0.0001 
Figure 2 Overall xenograft activity & clinical activity.
Agents were tested in a median of 12 xenografts (range 2–45) and a median
of 4 clinical diseases (range 1–24). The 33% cutoff was chosen
retrospectively to provide a useful benchmark which minimized false
negatives
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Figure 3 Mean log of GI50 versus percentage of compounds with hollow
fiber response in at least n fibers clinic. Indeed, the potential for this to emerge was a key rationale
for embarking on the 60 cell line screening paradigm (Alley et al,
1988). The difference in GI50 for any cell line and the average GI50
for all 60 cell lines was computed for the compounds studied in the
peritoneal fibres. The largest differential or ‘∆ ’ over the 60 cell
lines is recorded by cell type and value for each compound.
Table 5 shows that increasing ∆actually correlates negatively with
increasing likelihood of observance of activity in the HF model
(P < 0.0001). For example, the percentage of compounds which
respond in at least 4 i.p. fibres is greater with a ∆of ≤ 0.5 (45%)
than the percentage with ∆> 2 (26%). The same trend is displayed
when comparing ∆with xenograft activity, but the correlation is
not statistically significant (data not shown). 
The effect of molecular weight and the number of potential
hydrogen bonds in the compound structure on activity in the HF
assay were also examined. Compounds in low MW ranges (160 to
480) are generally considered to be more ‘drug-like’ than those in
higher ranges (Ghose et al, 1999). Interestingly, the number of
responsive i.p. fibres generally increases with increasing MW up
to a MW of 1000 (Table 6). For MW greater than 1000 activity
appears to decrease, but there are too few compounds of this size
level to generalize. In molecules with 7 to 10 potential hydrogen
bonds, 35% of compounds responded in a least 6 i.p. fibres versus
30% overall (P < 0.0001) (Table 7). This percentage increased to
43% in compounds with 11 or more potential hydrogen bonds.
Since, however, the number of heteroatoms contributes to both the
number of hydrogen bonds and MW, interdependence of MW and
hydrogen bond counts was examined and the results shown in
Table 8. Using the constant hydrogen bond range of 4 to 6, the
correlation between MW and HF activity was no longer statisti-
cally significant (P = 0.0895). However, using the constant MW
range of 250 to 500, the hydrogen bond parameter, now indepen-
dent of the effect of MW, still correlated strongly with HF response
(P < 0.0001) (Table 9). Neither MW or the number of hydrogen
bonds had any influence on activity in the s.c. fibres. The 
Correlations between preclinical and clinical activity 1429
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Table 5 Differential activity and HF activity 
Responsive IP fibres 
∆ 0 1–3 4–6 7–9 ³10 Total % with 4 or 
more fibres 
∆≤.5 34 76 33 20 36 199 45% 
0.5<∆≤ 1 138 427 154 46 50 815 31% 
1<∆≤ 1.5 179 389 138 38 42 786 28% 
1.5<∆≤2 77 150 55 21 18 321 29% 
∆>2 39 97 38 6 3 183 26% 
Total 467 1139 418 131 149 2304 30% 
c2 = 79.4, P < 0.0001 
Table 6 Molecular weight and HF activity 
Responsive IP fibres 
MW 0 1–3 4–6 7–9 ³10 Total % with 4 or 
more fibres 
MW≤ 250 47 102 27 11 2 189 21% 
250<MW≤ 500 330 815 311 78 103 1637 30% 
500<MW≤ 750 68 175 65 27 30 365 33% 
750<MW≤1000 14 25 10 13 7 69 43% 
MW>1000 8 22 4 1 7 42 29% 
Total 467 1139 417 130 149 2302 30% 
c2 = 55.3, P < 0.0001 
Table 7 Hydrogen bonding sites and HF activity 
Responsive IP fibres 
Potential H 0 1–3 4–6 7–9 ³10 Total % with 4 or 
bond sites more fibres 
0 to 3 110 233 70 21 8 442 22% 
4 to 6 226 577 223 53 58 1137 29% 
7 to 10 105 250 97 33 59 544 35% 
11 to 15 16 51 21 17 13 118 43% 
³16 10 28 7 7 11 63 40% 
Total 467 1139 418 131 149 2304 30% 
c2 = 88.3, P < 0.0001 
Table 8 Molecular weight and HF activity (independent of hydrogen bonding
sites) 
Responsive IP fibres 
(4–6 hydrogen bonding sites) 
MW 0 1–3 4–6 ³7 Total 
MW≤ 250 24 41 15 4 84 
250<MW≤ 500 178 488 186 101 953 
MW>500 27 48 19 6 100 
Total 229 577 220 111 1137 
c2 = 11.0, P = 0.0895 
Table 9 Hydrogen bonding and HF activity (independent of MW) 
Responsive IP fibres (250 <MW ≤500)
Potential 0 1–3 4–6 7–9  ³ 10 Total 
H-bond sites
0–3 86 163 55 14 8 326 
4–6 175 488 188 45 56 952 
³7 69 164 68 19 39 359 
Total 330 815 311 78 103 1534 
c2 = 35.8, P < 0.0001 
Table 4 Histological comparison between 60 cell line screen and hollow
fibre assay 
HF disease type I. II. c2 P
Breast 48% 39% 14.9 1.11E–04 
Colon 26% 27% 0.182 0.670 
Lung 65% 59% 10.7 0.00106 
Ovarian 55% 40% 14.5 1.42E–04 
CNS 58% 47% 15.9 <0.0001 
Melanoma 30% 25% 8.85 0.00293 
I. This column shows the activity rate for the HF tumour type where 4 or more
cell lines in the same 60 cell line disease panel were responsive. 
II. This column shows the overall activity rate for the HF tumour type for all
compounds tested. 1430 JI Johnson et al 
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relationship between these physiological properties and xenograft
activity had also been examined; although the same conclusions
could be drawn, the correlations were not as strong (data not
shown). 
According to the Lipinski Rule to Five (Lipinski et al, 1997),
compounds with more than 5 hydrogen bond donors (HBD) or
more than 10 hydrogen bond acceptors (HBA) are more likely to
have poor oral absorption. Among the compounds tested in the HF
assay, 95% had less than 5 HBD and 95% less than 10 HBA; since
the percentages of compounds with favourable HBD and HBA
counts was so great, an analysis of the effect of these parameters
was not performed. In fact, these parameters were identical to the
compounds entering the in vitro screening system. 
Unfortunately, only about 75% of compounds selected for the
HF assay are tested in that system, primarily due to problems with
insufficient supply of compound. The 25% of selected but not
tested compounds represent a potential source of bias in these
analyses, particularly as the compounds for which it is not possible
to obtain the quantities necessary for in vitro testing might repre-
sent greater structural complexity. In fact, the mean MW of non-
tested compounds was 485 (vs 420 for tested compounds), with
only approximately 1.3 additional H bond sites per molecule (data
not shown). 
DISCUSSION 
The analysis of xenograft versus clinical results illustrates that a
histology to histology comparison of these models to activity in
the clinic cannot be reliably discerned for these ‘empirically’
selected compounds acting against non-molecularly characterized
tumours. Although, with the exception of lung, histological
matches were not found between in vivo models and clinical
response, activity in multiple xenograft models does appear to
predict for some degree of clinical activity. Interestingly,
increasing the activity threshold to a T/C of ≤10 did not increase
the likelihood of a positive clinical outcome, indicating that this
activity threshold is probably too stringent. Requiring greater clin-
ical activity (activity in 2 or more diseases) does improve the
correlation between xenograft activity and clinical activity.
Although the more stringent definition of clinical activity may not
be suitable for making decisions on whether to advance agents
from phase II to phase III trials, as a purely statistical exercise, it
does support the conclusion that activity in multiple xenograft
models is a useful predictor of clinical activity. 
In contrast to results achieved with the DTP xenograft system,
Fiebig (Scholz et al, 1990) has developed xenograft tumours
which retain characteristics similar to the clinical specimens,
having been grown from slow-growing and well-differentiated cell
lines. Fiebig reports that when treating these xenograft tumours
with the same standard agents as were utilized in the clinic for the
corresponding patient tumours, the response of these xenografts in
comparison to patient tumours was 90% (19/21) for sensitive and
97% (57/59) for non-responding tumours respectively. While this
degree of correspondence between clinically used agent activity in
xenografts and the clinic is gratifying, it is uncertain how to trans-
late that experience to the evaluation of new agents with no prior
defined clinical activity. As the clinically used standard agents
have in all cases proven active in many xenograft models, this
result at one level might be in accord with our finding that the
number of xenografts in which an agent is active correlates with
likely activity in the clinical setting. 
The results presented in Figures 1 and 2 may be taken to argue
against the use of activity in an empirically selected xenograft
model to predict activity in the same histologic type of cancer in
the clinic, and indeed that result has influenced the current
philosophy underlying NCI’s drug discovery and development
programme (Sausville and Feigal, 1999). Nonetheless, definition
of an active agent in xenografts would allow optimization of
schedule, assessment of molecular target endpoints, and increase
the probability of clinical activity. It is therefore beneficial to have
the ability to select agents with a likelihood of xenograft activity
using a rapid and inexpensive test. The HF assay was developed to
serve as a discriminator for compounds emerging from an empir-
ical in vitro cell line screen. Our analyses indicate that greater
levels of response in the i.p. fibres correlate with greater likelihood
of xenograft activity. The same cannot be stated for responses in
the s.c. fibres. Double (Phillips et al, 1998) reports that the NCI
protocol for HF does not allow sufficient time for angiogenesis to
occur, and hypothesizes that s.c. response may be underestimated
with NCI’s protocol. Folkman (Hahnfeldt et al, 1999), however,
claims that a tumour does not require vessels until it is 3–4 mm in
diameter; the polyvinylidene fibres are only 1 mm. Subcutaneous
response is dependent on extravascular drug concentration, so the
lack of correlation between s.c. fibres response and xenograft
activity may be speculatively related to factors such as dose, route,
schedule, hydrostatic pressure and hydration state of the host. 
As with xenograft to clinical comparisons, activity against a
single specific HF histology was generally not useful for
predicting xenograft activity in the same histology. The lack of
histologic correlations in this case can perhaps be explained by the
minimal number (2 of each histology) in the HF assay. In contrast,
most panels in the 60 cell line in vitro assay consist of a minimum
of 6 different cell types, so cell panel specificity is more readily
defined. Note that the correlations between in vitro and either HF
or xenografts are only apparent when 4 or more cell lines respond. 
The examination of the in vitro screening data indicate strong
histologic correlations with HF activity for all panels but colon,
while indications of differential activity (high ‘D’), did not corre-
late with HF activity. This observation combined with that of the
correlation of HF response with increasing in vitro potency may
indicate that the standard HF assay is sensitive to strongly cyto-
toxic as opposed to ‘differentially’ acting agents. It can also be
taken to indicate that if differential activity is truly suggested from
in vitro results, a HF experiment addressing that particular set of
cell types may need to be designed or specific target manipulation
should be considered. 
Our analysis of MW and hydrogen-bonding factors revealed a
correlation between increasing MW, as well as greater hydrogen-
bonding sites and HF activity. This suggests that in choosing test
agents for further development, a compromise should be made
between low MW for drug development purposes and the number
of hydrogen-bonding sites for efficacy. HBA and HBD counts
were not revealing, as 95% of the input to the in vitro screen was in
the favourable range for these factors. 
These results may be considered to define a ‘road-map’ for
charting the transition of a compound from an in vitro screening
result to a clinical candidate. If the development strategy of a
compound is to remain empiric, consideration of the heteroge-
neous nature of in vivo model to clinical correlation might require
strategies to define the likelihood of clinical activity, and again
overall potency and activity in a large number of HF fibres might
allow the best delineation of compounds to consider for furtherCorrelations between preclinical and clinical activity 1431
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development. It could be argued from this experience that
compounds with an anti-proliferative effect at 10–6 M have a rela-
tively higher likelihood of affecting all growth in a responsive
tumour. Compounds of the future will likely be advanced to clin-
ical testing with an eye toward addressing a defined molecular
abnormality or target in the tumour cell. Greater numbers (n ³ 4)
of redundant cell types expressing the target, whether in an in vitro
assay such as the 60 cell line screen, or an in vivo assay such as the
HF assay, might be expected to have concordant effects in xeno-
grafts bearing the same target. Finally, as efforts are consolidated
to derive engineered animal strains to provide models of
tumour biology and pathophysiology (http://www.nci.nih.gov/dcb/
odhome.htm#MOUSE), consideration of the ‘baseline’ experience
of an empirically oriented drug discovery program might usefully
benchmark the types of compounds suitable for advancement to
such models. 
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